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By using p65 synaptotagmin-1 and fibroblast growth
factor (FGF)-1:b-galactosidase (b-gal) NIH 3T3 cell co-
transfectants, we demonstrate that a proteolytic frag-
ment consisting of the extravesicular domain of synapto-
tagmin-1 is released into the extracellular compartment
in response to temperature stress with similar kinetics
and pharmacological properties as FGF-1:b-gal. Using
a deletion mutant that lacks 95 amino acids from the
extravesicular domain of synaptotagmin-1, neither
synaptotagmin-1 nor FGF-1:b-gal are able to access the
stress-induced release pathway. Furthermore, the p40
extravesicular fragment of synaptotagmin-1 is constitu-
tively released in p40 synaptotagmin-1 NIH 3T3 cell
transfectants, and this release is potentiated when the
cells are subjected to temperature stress. These data
demonstrate that the p40 fragment derived from synap-
totagmin-1 is able to utilize the FGF-1 non-classical exo-
cytotic pathway and that the release of FGF-1 is depend-
ent on synaptotagmin-1.
FGF1-1 and FGF-2 are the prototype members of a large
family of related heparin-binding growth factors that regulate
numerous biological processes including mesoderm formation,
neurogenesis, and angiogenesis in vivo (1). The FGF prototypes
are distinguished among the FGF family members by the ab-
sence of a classical signal peptide sequence to direct their
secretion through the conventional endoplasmic reticulum
(ER)-Golgi pathway. Because the FGF prototypes initiate their
biological responses through the activation of high affinity re-
ceptors on the surface of target cells, it has been suggested that
the secretion of both FGF-1 and FGF-2 may be regulated by
novel release pathways. Indeed, the ligation of a signal peptide
sequence to FGF-1 followed by somatic gene transfer, which
results in the constitutive release of FGF-1, yields a functional
oncogene in vitro and exaggerated vascular hyperplasia in vivo
(2, 3).
We have reported that FGF-1 is released from stable FGF-1
NIH 3T3 cell transfectants through a non-classical exocytotic
pathway as a latent macromolecule in response to temperature
stress which requires activation by either (NH4)2SO4 (4) or
reducing agents (5–7). During the structural characterization
of FGF-1 (8), a heparin-binding protein (p40) that co-eluted
with FGF-1 was identified by amino-terminal sequence analy-
sis as a proteolytic fragment of the synaptotagmin-1 (Syn-1)
translation product (8). Syn-1 is a 65-kDa vesicular protein and
has been most extensively studied in neuronal and endocrine
cells. The Syn gene family currently consists of 11 members (9,
10) and is characterized by a divergent amino terminus, a
transmembrane domain, a large cytoplasmic region, which is
comprised of two repeats of sequences homologous to the pro-
tein kinase C C2 domain, and a highly conserved carboxyl
terminus (11, 12). The p40 proteolytic fragment identified in
neural tissue corresponds to the extravesicular portion of
Syn-1. Genetic and microinjection studies have suggested that
Syn-1 is the Ca21 sensor for neurotransmitter release (13).
Recently, our laboratory has identified the presence of the
Syn-1 transcript and translation product in NIH 3T3 cells, as
well as in human umbilical vein endothelial cells (14). More-
over, we have detected the p40 extravesicular portion of Syn-1
in the conditioned medium from FGF-1-transfected cells ex-
posed to heat shock and have observed that the release of
FGF-1 in response to temperature stress can be significantly
attenuated by the expression of an antisense-Syn-1 construct
(14). Since these data indicate that Syn-1 may be involved in
the non-classical secretion pathway employed by FGF-1, we
used an established in vitro system (4) to study the properties
of Syn-1 release. NIH 3T3 cells stably transfected with a FGF-
1:b-galactosidase (gal) chimera construct release the FGF-1:b-
gal chimera as a structurally intact protein in response to
temperature stress (15). Because the endogenous level of Syn-1
expression is low in NIH 3T3 cells, we used FGF-1:b-gal NIH
3T3 cells co-transfected with either p65 Syn-1 or a construct
expressing the p40 extravesicular domain of the Syn-1 protein
to study the release pathway used by these polypeptides. We
report that the p40 extravesicular portion of Syn-1 is released
from p65 Syn-1 and FGF-1:b-gal co-transfectants in response to
temperature stress with similar kinetics as FGF-1:b-gal. The
release of both Syn-1 and FGF-1:b-gal is an ATP-driven process
that requires transcription and translation but does not require
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a structurally intact ER-Golgi apparatus. Deleting 95 amino
acids from the extravesicular domain of Syn-1 results in a
mutant Syn-1 that is not released in response to temperature
stress and also prevents the release of FGF-1:b-gal into the
heat shock conditioned medium. Transfecting a construct en-
coding only the extravesicular domain of Syn-1 into FGF-1:b-
gal NIH 3T3 cells results in the constitutive release of the p40
extravesicular fragment of Syn-1, and this release is potenti-
ated when the cells are subjected to temperature stress. Al-
though the constitutive release of p40 Syn-1 from these co-
transfectants is not energy-dependent, the potentiated release
requires ATP. However, both the constitutive release and the
potentiated release are ER-Golgi-independent.
EXPERIMENTAL PROCEDURES
Cell Culture—Murine NIH 3T3 cells were obtained from the Ameri-
can Type Culture Collection, and stable NIH 3T3 FGF-1:b-gal cell
transfectants were obtained as described previously (15). Cells were
transfected with a eukaryotic expression vector containing a gene en-
coding resistance to hygromycin and the coding sequence for rat p65
Syn-1 (amino acids 1–421) or rat p65-(del 120–214) or rat p40 Syn-1
(amino acids 119–421) containing a Myc tag. Co-transfectants were
maintained in Dulbeccos’s modified Eagle’s medium (DMEM, Life Tech-
nologies, Inc.) containing 10% (v/v) bovine calf serum (BCS, HyClone),
13 antibiotic/antimycotic (Life Technologies, Inc.), and 200 mg/ml G418
(Life Technologies, Inc.) and 250 mg/ml hygromycin (Boehringer Mann-
heim) on human fibronectin (10 mg/cm2)-coated dishes.
Synaptotagmin Constructs—The p65 form of rat Syn-1 (a generous
gift of T. C. Sudhof) was cloned into the PCRII vector (Invitrogen, San
Diego) after generating an NdeI site at the amino terminus and a
BamHI site at the carboxyl terminus by polymerase chain reaction. The
Myc-tag (59-GAACAAAAGCTTATTTCTGAAGAAGACTTG-39) was li-
gated to the carboxyl terminus and consisted of a 10-amino acid
(EQKLISEEDL) epitope recognized by the 9E10 monoclonal antibody
(16). The p65-(del 120–214) construct was made by removing the AflII-
KpnI fragment from the p65 Syn-1 construct resulting in the loss of
amino acids 120–214 and the addition of 3 amino acids (GID). The p40
form of rat Syn-1 was made by deleting the 59 sequences at the AflII site
and thus generated a construct that encoded for amino acids 119–421,
which includes the C2A and C2B domains and the conserved carboxyl
terminus, as well as the Myc tag. For transfection analysis p65 Syn-1,
p65-(del 120–214) and p40 Syn-1 were cloned into the pMEXhygro
vector. This vector was generated from the pMEXneo vector (17) by
removing the StuI-NruI fragment containing the neomycin resistance
gene and inserting a 1774-base pair HpaI-Eco3I fragment containing
the hygromycin B resistance promoter and gene from the p39SS vector
(Stratagene).
Temperature Stress and Processing of the Condition Medium—For
heat shock, the transfected cells were grown to confluence in DMEM
containing 10% (v/v) BCS and 13 antibiotic/antimycotic on human
fibronectin (10 mg/cm2)-coated dishes; the cells were washed with
DMEM containing 4 units/ml heparin (The Upjohn Co.) and subjected
to heat shock (42 °C for 100 min) in DMEM containing 4 units/ml
heparin and 0.5% BCS as described previously (4). Three independent
clones were tested for each transfection. In order to study the biochem-
ical properties of secretion, prior to heat shock the transfectants were
incubated at 37°C with either 10 mg/ml actinomycin D (2 h, added from
a 1 mg/ml stock solution in ethanol; Sigma), 10 mg/ml cycloheximide (2
h, added from a 10 mg/ml stock solution in Me2SO; Sigma), 5 mg/ml
brefeldin A (0.5 h, added from a 1 mg/ml stock solution in ethanol;
Epicenter Technologies), 50 mM 2-deoxyglucose (1 h; Sigma), or 5 mM
A23187 (Sigma); the transfectants were washed with DMEM contain-
ing 4 units/ml heparin and then subjected to heat shock (42 °C for 100
min) in DMEM containing 4 units/ml heparin and 0.5% BCS in the
presence of the drug, except for A23187, which was performed as
described under “Results.” Conditioned media were collected after tem-
perature stress, processed by filtration, and activated with 0.1% (w/v)
dithiothreitol (DTT, Sigma) by incubating at 37 °C for 2 h (5). The
conditioned medium was adsorbed to a 1-ml heparin-Sepharose CL-6B
column (Amersham Pharmacia Biotech) equilibrated with 50 mM Tris,
pH 7.4, containing 10 mM EDTA (TEB). The column was washed with
TEB and then eluted with TEB containing 1.5 M NaCl. The eluant was
concentrated using a Centricon 10 concentrator (Amicon, Inc.) and
analyzed by 10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) as described previously (5). To examine the cell
lysate, cells were collected, pelleted, and lysed in sample buffer; a
fraction of the cell lysate was analyzed by 10% SDS-PAGE.
Cell viability was assessed by measuring lactate dehydrogenase
(LDH) activity in the conditioned medium after filtration as described
by Bergmeyer (18) (Sigma procedure DG 1340-UV). To determine total
LDH activity cells were lysed in PBS containing 1% Triton X-100 and
sonicated. The debris was pelleted, a 1:80 dilution of the cell lysate was
made, and LDH activity was measured. This value was used to deter-
mine the percent of LDH activity in the conditioned medium.
Immunoblot analysis of the samples resolved by SDS-PAGE was
performed as described previously (4). Briefly, after transfer to a nitro-
cellulose filter, the filters were incubated with 24 mM Tris, pH 7.4,
containing 136 mM NaCl, 2 mM KCl, and 0.1% (v/v) Tween 20 (TCB) that
contained 5% (w/v) milk for 2 h at 42 °C. The filter was probed with
either 5 mg/ml polyclonal anti-human FGF-1 antibody (19) or 5 mg/ml
polyclonal anti-rat Syn-1 antibody (14) in TCB containing 5% milk for
1 h at room temperature. The filter was washed with TCB and then
visualized using the ECL detection system (Amersham Pharmacia
Biotech).
RESULTS
The Kinetics of p40 Syn-1 Release in Response to Tempera-
ture Stress—Consistent with the results in cell lysates from
NIH 3T3 cells that are not transfected with p65 Syn-1, which
have been adsorbed to and eluted from heparin-Sepharose, the
lysate from the p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-
transfectants resolves several heparin-binding Syn-1 immuno-
reactive polypeptides as visualized by Syn-1 immunoblot anal-
ysis (compare Fig. 1, A with B). Tunicamycin treatment and
pulse-chase analysis of the p65 NIH 3T3 cell transfectants
(data not shown) demonstrated that these polypeptides are
partially due to differential N-glycosylation, an observation
consistent with reports that Syn-1 is N-glycosylated and palmi-
toylated (20, 21). To determine the kinetics of release of Syn-1,
p65 Syn-1 was stably transfected into FGF-1:b-gal NIH 3T3
cell transfectants, and the heat shock-conditioned medium
from the co-transfectants was collected and examined after
adsorption to and elution from heparin-Sepharose. The p40
extravesicular fragment of Syn-1 was clearly detectable in the
conditioned medium after 1.5 h at 42 °C (Fig. 2A). Supplement-
ing the medium with protease inhibitors did not influence the
generation of p40 Syn-1 (data not shown). Analysis of the heat
shock-conditioned medium using FGF-1 immunoblot methods
demonstrated that FGF-1:b-gal is also released with similar
kinetics (Fig. 2B). Lactate dehydrogenase (LDH) activity was
FIG. 1. A comparison of the endogenous Syn-1 immunoreactive
polypeptides with the transfected rat p65 Syn-1 polypeptides.
FGF-1 NIH 3T3 cell transfectants (A) or p65 Syn-1 and FGF-1:b-gal
NIH 3T3 cell co-transfectants (B) were collected and lysed in PBS
containing 1% Triton. The lysate was adsorbed to heparin-Sepharose
and eluted with increasing concentrations of NaCl, resolved by 10%
SDS-PAGE and immunoblotted for Syn-1. Lane 1, 0.25 M NaCl; lane 2,
0.4 M NaCl; lane 3, 0.6 M NaCl; lane 4, 0.8 M NaCl; lane 5, 1.0 M NaCl;
and lane 6, 1.5 M NaCl. Approximately 9-fold more cell lysate was used
in A than in B and approximately an 8-fold longer exposure of the
immunoblot was needed for A than B.
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measured to demonstrate that the cells did not undergo signif-
icant lysis after the cells were subjected to temperature stress.
We typically observed 5.6% of the total cell lysate LDH activity
in the medium conditioned at 37 °C for 100 min and 8.5% of the
total cell lysate LDH activity in the medium conditioned by
heat shock (42 °C, 100 min).
Because FGF-1 NIH 3T3 cell transfectants co-transfected
with an antisense-Syn-1 construct are impaired in their ability
to release FGF-1 in response to temperature stress (14), we
evaluated whether Syn-1 release was dependent on FGF-1
expression. The p65 Syn-1 NIH 3T3 cell transfectants, which
have very low levels of endogenous FGF-1 and p65 Syn-1 NIH
3T3 cells co-transfected with a Cys-free mutant non-secreted
form of FGF-1 (5), demonstrated that the release of p40 Syn-1
was similar to that observed in the p65 Syn-1 and FGF-1:b-gal
NIH 3T3 cell co-transfectants (Fig. 3, A and B). These data
suggest that p40 Syn-1 release from the p65 Syn-1 and FGF-
1:b-gal NIH 3T3 cell co-transfectants in response to heat shock
does not depend on the expression of high levels of cytosolic
FGF-1 that is competent to enter the stress-induced release
pathway.
The Pharmacology of p40 Syn-1 Release in Response to Tem-
perature Stress—We have previously demonstrated that the
release of FGF-1 is dependent on both transcription and pro-
tein synthesis because FGF-1 release is blocked by exposure to
either actinomycin D or cycloheximide (4). Furthermore, FGF-1
utilizes a non-classical release mechanism since its appearance
in the extracellular compartment is not sensitive to treatment
with brefeldin A (Fig. 4B, lane 3–5 (4)). Thus, we analyzed the
effects of actinomycin D, cycloheximide, and brefeldin A on the
release of Syn-1. Consistent with the results obtained for the
release of FGF-1 (4), we observed that the release of p40 Syn-1
is inhibited by actinomycin D and cycloheximide, and its re-
lease is insensitive to treatment with brefeldin A (Fig. 4A, lanes
3–5). Additionally, FGF-1 is released into the heat shock con-
ditioned medium as a latent low heparin-binding affinity com-
plex that must be activated with either (NH4)2SO4 or DTT in
order to bind immobilized heparin with high affinity (4, 14).
Heparin eluates of conditioned medium from temperature
stress-induced p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-
transfectants that are not activated by DTT contain lower
levels of p40 Syn-1 and FGF-1:b-gal (Fig. 4, A and B, lane 7).
These results suggest that the secreted p40 Syn-1 and FGF-1:
b-gal exhibit reduced heparin affinity when the conditioned
medium is not activated with DTT.
It has been suggested that Syn-1 is the Ca21 sensor during
neurotransmitter release (22). Furthermore, ATP and calcium
have been demonstrated to play an important role in regulated
exocytotic pathways. Thus, we sought to determine whether
these cofactors play a role in the release of either Syn-1 or
FGF-1:b-gal. To determine the ATP requirement for the release
of these polypeptides, the NIH 3T3 cell co-transfectants were
subjected to heat shock in the presence of 2-deoxyglucose
(dOG), an analog of glucose that inhibits glycolysis and thus
the generation of ATP (23). As shown in Fig. 4, A and B (lane 6),
the release of both p40 Syn-1 and FGF-1:b-gal in response to
temperature stress was severely reduced in the presence of
2-dOG. To assess whether an increase in intracellular Ca21
concentration would have an effect on FGF-1:b-gal and p40
Syn-1 release, the p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell
co-transfectants were pretreated with the Ca21 ionophore,
A23187, at 37 °C and then subjected to heat shock in the
absence of the drug. Surprisingly, A23187 did not affect the
release of either p40 Syn-1 (Fig. 5A) or FGF-1:b-gal (Fig. 5B) at
37 or at 42 °C. Additionally, treating the cells with the iono-
phore at 37 °C for up to 2 h did not stimulate the release of p40
Syn-1 or FGF-1:b-gal (data not shown). Unfortunately, we were
unable to assess whether treating the cells with the ionophore
for longer intervals during heat shock has an effect on either
p40 Syn-1 or FGF-1:b-gal release since these conditions re-
sulted in cell lysis. Ca21 is generally considered to be a tran-
sient stimulant, and pretreating the cells prior to temperature
stress may not deliver the increase in intracellular Ca21 at the
appropriate time. Therefore, we subjected the p65 Syn-1 and
FGF-1:b-gal NIH 3T3 cell co-transfectants to heat shock for
1.5 h, added the ionophore, and continued the heat shock in the
presence of A23187 for 15 min. Similar to the pretreatment of
the cells with the ionophore, delivering the Ca21 signal 1.5 h
into the heat shock had no effect on the release of either p40
Syn-1 or FGF-1:b-gal (data not shown).
The Release of Both Syn-1 and FGF-1:b-gal Is Dependent on
Residues 120–214 in p65 Syn-1—To investigate further
whether Ca21 might play a role in this release mechanism, a
95-amino acid deletion was made in p65 Syn-1 that deleted the
Ca21-binding site, the phosphatidylserine-binding domain, and
the casein kinase II phosphorylation site (39, 42) (Fig. 6A).
Similar to the p65 Syn-1 lysate, the p65-(del 120–214) lysate
contained several immunoreactive Syn-1 polypeptides, includ-
ing a 35-kDa fragment suggesting that the deletion mutant is
competent to generate a soluble extravesicular domain (Fig.
6B, lane 2). However, examining the heat shock conditioned
medium of the p65-(del 120–214) and FGF-1:b-gal NIH 3T3
co-transfectants showed that neither p65-(del 120–214) (Fig.
6B) nor FGF-1:b-gal (Fig. 6C) was present in the extracellular
compartment. These data suggest that this 95-amino acid re-
gion is required for both Syn-1 and FGF-1:b-gal to access the
stress-induced release pathway.
The p40 Syn-1 Domain Is Released from NIH 3T3 Cells
Independent of Temperature Stress—The detection of only the
p40 extravesicular portion of p65 Syn-1 in the extracellular
FIG. 2. The release kinetics of the extravesicular domain of Syn-1 and FGF-1:b-gal from NIH 3T3 cells in response to temperature
stress. Lysate and conditioned medium from p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants were collected at various times and
immunoblot analysis for Syn-1 (A) and FGF-1:b-gal (B) were performed as described under “Experimental Procedures.” Lanes 1 and 2 are the
lysates from p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell transfectants at 37 °C (2 h) and 42 °C (2 h), respectively. Lanes 3–7 are the conditioned
medium from cells treated at 37 °C; lane 3, 2 h or at 42 °C; lane 4, 0.25 h; lane 5, 0.5 h; lane 6, 1.0 h; lane 7, 1.5 h; lane 8, 2.0 h. The arrow in A
denotes the p40 extravesicular fragment of Syn-1, and the arrow in B denotes FGF-1:b-gal.
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compartment suggests the function of a protease that may be
important to relieve p65 Syn-1 from its transmembrane con-
straint. The activity of this protease may be induced by tem-
perature stress and thus may be a regulated step in the Syn-1
exocytotic pathway. To determine whether the generation of
the p40 proteolytic fragment of Syn-1 is regulated, we stably
co-transfected a construct expressing the p40 extravesicular
fragment of Syn-1 into the FGF-1:b-gal NIH 3T3 transfectants
and examined the conditioned medium for the presence of p40
Syn-1 and FGF-1:b-gal prior to and after heat shock. Interest-
ingly, we observed the constitutive release of the p40 Syn-1
fragment at 37 °C (Fig. 7A). In addition, we did not observe an
increase in the release of FGF-1:b-gal at 37 °C from the p40
Syn-1 and FGF-1:b-gal co-transfectants (Fig. 7B). Further-
more, following temperature stress, the release of p40 Syn-1
was potentiated in the p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell
co-transfectants (Fig. 7A, lanes 4 and 5). Consistent with the
results observed with the p65 Syn-1 and FGF-1:b-gal NIH 3T3
cell co-transfectants, the release of p40 Syn-1 (Fig. 7A, compare
lanes 4 and 5 with lanes 6 and 7) and FGF-1:b-gal (Fig. 7B)
from the p40 Syn-1 and FGF-1:b-gal co-transfectants was un-
affected by treatment with brefeldin A. In contrast, however,
the release of p40 Syn-1 from the p40 Syn-1 and FGF-1:b-gal
NIH 3T3 cell co-transfectants was not attenuated at 37 °C in
the presence of 2-dOG (Fig. 7C compare lanes 4 and 6), but the
potentiation of p40 Syn-1 release and the release of FGF-1:b-
gal upon heat shock was inhibited in the presence of 2-dOG
(Fig. 7C compare lanes 5 and 7 and Fig. 7D compare lanes 4 and
6). These data suggest that the release of p40 Syn-1 may not be
regulated by the conditions of temperature stress, rather it
may be regulated by the function of a protease whose activity is
induced by temperature stress.
DISCUSSION
Syn-1 has been characterized as a constituent of a multipro-
tein complex involved in the regulation of neurotransmitter
release. Although Syn-1 is thought to be the Ca21 sensor for
neurotransmitter release, Syn-1 Ca21-independent interac-
tions have been identified, and several of the Syn family mem-
bers have been reported to function in a Ca21-independent
manner (9, 22). Our attempts to increase the intracellular
concentration of Ca21 by treating the cells with the ionophore
A23187 did not stimulate the release of either Syn-1 or FGF-
1:b-gal in vitro, suggesting that this release mechanism may
utilize a component of the Ca21-independent function of Syn-1.
However, we cannot conclude that Ca21 does not play a role in
this non-classical release mechanism, since it is possible that
the ionophore was not delivered either at the appropriate time
or in the appropriate cellular context, or perhaps it may need
additional co-factors to function in this pathway. Moreover,
deleting residues 120–214 from Syn-1 blocks the release of
both Syn-1 and FGF-1 in response to temperature stress. This
region contains the Ca21-binding site, the phosphatidylserine-
binding site, and the casein kinase II phosphorylation site (39,
42) and thus suggests that one of these activities may be
required in this release mechanism. Likewise, 2-dOG affects
the generation of ATP and thus a number of cellular processes
including glycosylation. Whereas the decrease in the tempera-
ture stress-induced release of both Syn-1 and FGF-1:bgal in the
presence of 2-dOG suggests that ATP may play a role in this
pathway, we cannot conclude what is the exact mechanism by
which ATP is utilized.
Even though the FGF-1 non-classical release pathway is
utilizing components of the classical exocytotic pathway, the
mechanism of FGF-1 release appears to be novel. It has been
proposed that during neurotransmitter release, Syn-1 facili-
tates the docking of the vesicle at the plasma membrane and
then, in an ATP-dependent step, the vesicle fuses with the
plasma membrane and subsequently releases the vesicular
FIG. 3. The release of the extravesicular domain of p65 Syn-1 is not dependent on high levels of FGF-1 that are able to access the
stress-induced exocytotic pathway. A, lysate and conditioned medium were collected, and immunoblot analysis for Syn-1 was performed as
described under “Experimental Procedures.” Lane 1 is the lysate from p65 Syn-1 NIH 3T3 cell transfectants at 37 °C. Lane 2 is the lysate from p65
Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants at 37 °C. Lanes 3 and 4 are the conditioned medium from p65 Syn-1 NIH 3T3 cell
transfectants treated at 37 °C (100 min) or at 42 °C (100 min), respectively. Lanes 5 and 6 are the conditioned medium from p65 Syn-1 and
FGF-1:b-gal NIH 3T3 cell co-transfectants treated at 37 °C (100 min) or at 42 °C (100 min), respectively. B, lysate and conditioned medium were
collected, and immunoblot analysis for Syn-1 was performed as described under “Experimental Procedures,” except cells were lysed in PBS
containing 1% Triton X-100, and lysate was adsorbed to heparin-Sepharose and eluted at 1.5 M NaCl. Lane 1 is the lysate from p65 Syn-1 and
FGF-1:b-gal NIH 3T3 cell co-transfectants at 37 °C. Lane 2 is the lysate from p65 Syn-1 and Cys-free FGF-1 NIH 3T3 cell co-transfectants at 37 °C.
Lanes 3 and 4 are the conditioned medium from p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants treated at 37 °C (100 min) or at 42 °C
(100 min), respectively. Lanes 5 and 6 are the conditioned medium from p65 Syn-1 and Cys-free FGF-1 NIH 3T3 cell co-transfectants treated at
37 °C(100 min) or at 42 °C (100 min), respectively.
FIG. 4. The biochemical properties of the release of the ex-
travesicular domain of Syn-1 and FGF-1:b-gal from NIH 3T3
cells. The p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants
were treated, and conditioned medium was collected, and immunoblot
analyses for Syn-1 (A) and FGF-1:b-gal (B) were performed as described
under “Experimental Procedures.” Lanes 1 and 2 are conditioned me-
dium collected from untreated cells at 37 and 42 °C, respectively. Lanes
3–6 are heat shock conditioned medium from cells treated with the
following: lane 3, actinomycin D; lane 4, cycloheximide; lane 5, brefeldin
A; lane 6, 2-dOG; and lane 7 is heat shock conditioned medium not
activated with DTT. Figure is a composite of several experiments. The
levels of Syn-1 and FGF-1:b-gal expression in cell lysate were unaf-
fected by treatment with the various drugs (data not shown). LDH
activity was measured to demonstrate that the cells did not undergo
significant lysis in the presence of the drugs and temperature stress:
37 °C 5.6%, 42 °C 8.5%, actinomycin D 11.0%, cycloheximide 8.9%,
brefeldin A 10.4% and 2-dOG 7.8%.
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contents into the extracellular compartment (23). In contrast,
we have observed the release of the extravesicular (cytoplas-
mic) domain of Syn-1 (p40) into the medium conditioned by
heat shock, and our data suggest that the release of p40 Syn-1
in response to stress occurs by an ER-Golgi-independent mech-
anism that requires time, energy, transcription, and transla-
tion. These features are also conserved within the non-classical
FGF-1 release pathway, and the release of both polypeptides
requires a 95-amino acid domain contained within the extrave-
sicular portion of Syn-1.
The data presented here demonstrate that Syn-1 is required
for the release of FGF-1 and, more specifically, that it is the
sequences within the extravesicular domain of Syn-1 that are
involved in the regulation of this release. Moreover, these data
confirm our prior observation that antisense-Syn-1 NIH 3T3
cell transfectants are attenuated in their ability to release
FGF-1 in response to temperature stress (14). Syn-1 has been
demonstrated to bind a large number of proteins and phospho-
lipids, and the majority of these interactions are mediated by
the C2 domains in the extravesicular portion of Syn-1 (9, 24,
25). Although deleting residues 120–214 from Syn-1 results in
a dominant-negative mutant Syn-1 that blocks FGF-1:b-gal
release, when either p40 Syn-1 or p65 Syn-1 was co-transfected
into FGF-1:b-gal NIH 3T3 cells, we did not observe an increase
in FGF-1:b-gal release in response to temperature stress when
compared with singly transfected FGF-1:b-gal NIH 3T3 cell
FIG. 5. Raising the intracellular concentration of calcium does not stimulate the release of Syn-1 or FGF-1:b-gal. The p65 Syn-1 and
FGF-1:b-gal NIH 3T3 cell co-transfectants were pre-treated with A23187 for 15 min, washed, and incubated in the absence of drug at 37 or 42 °C
for 100 min; conditioned medium was collected, and immunoblot analyses for Syn-1 (A) and FGF-1:b-gal (B) were performed as described under
“Experimental Procedures.” A, Syn-1 immunoblot. Lanes 1 and 2 are lysate collected from untreated cells at 37 and 42 °C, respectively. Lane 3 is
50 ng of recombinant rat Syn-1 extravesicular domain. Lanes 4 and 5 are conditioned medium collected from untreated cells at 37 °C and 42 °C,
respectively. Lanes 6 and 7 are conditioned medium collected from cells pretreated with the ionophore at 37 and 42 °C, respectively. B, FGF-1
immunoblot. Lanes 1 and 2 are cell lysates collected from untreated cells at 37 and 42 °C, respectively. Lanes 3 and 4 are conditioned medium
collected from untreated cells at 37 and 42 °C, respectively. Lanes 5 and 6 are conditioned medium collected from cells pretreated with the
ionophore at 37 and 42 °C, respectively. LDH values in the presence of A23187 were 5.8% at 37 °C and 11.7% at 42 °C
FIG. 6. Deleting residues 120–214 results in a mutant Syn-1 that inhibits the release of both Syn-1 and FGF-1:b-gal. A, a schematic
illustration of the domain structure of p65 Syn-1 (top) and the site of the deletion in p65-(del 120–214) (bottom). TM represents the transmembrane
region; A, the first C2 domain; B, the second C2 domain. The p40 extravesicular portion of Syn-1 that is released into the heat shock conditioned
medium is denoted. B, lysate and conditioned medium were collected, and immunoblot analysis for Syn-1 was performed as described under
“Experimental Procedures.” Lane 1 is the lysate from p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants at 37 °C. Lane 2 is the lysate from
p65-(del 120–214) and FGF-1:b-gal NIH 3T3 cell co-transfectants at 37 °C. Lane 3 is 50 ng of recombinant rat Syn-1 extravesicular domain. Lanes
4 and 5 are the conditioned medium from p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell transfectants treated at 37 °C (100 min) or at 42 °C (100 min),
respectively. Lanes 6 and 7 are the conditioned medium from p65-(del 120–214) and FGF-1:b-gal NIH 3T3 cell co-transfectants treated at 37 °C
(100 min) or at 42 °C (100 min.), respectively. Arrow indicates p40 Syn-1. C, lysate and conditioned medium were collected, and immunoblot
analysis for FGF-1 was performed as described under “Experimental Procedures.” Lane 1 is the lysate from p65 Syn-1 and FGF-1:b-gal NIH 3T3
cell co-transfectants at 37 °C. Lane 2 is the lysate from p65-(del 120–214) and FGF-1:b-gal NIH 3T3 cell co-transfectants at 37 °C. Lanes 3 and 4
are the conditioned medium from p65 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants treated at 37 °C (100 min) or at 42 °C (100 min),
respectively. Lanes 5 and 6 are the conditioned medium from p65-(del 120–214) and FGF-1:b-gal NIH 3T3 cell co-transfectants treated at 37 °C
(100 min) or at 42 °C (100 min), respectively. Arrow denotes FGF-1:b-gal.
The FGF-1 Release Pathway II 22221
transfectants. Moreover, p40 Syn-1 was released following
transfection into NIH 3T3 cells that do not overexpress FGF-1
or that express the cysteine-free mutant FGF-1 that is not
competent to enter the release pathway (Fig. 3). FGF-1:b-gal
release may not be increased when either p40 Syn-1 or p65
Syn-1 is overexpressed because, similar to the regulation of the
conventional secretion pathway, this non-classical pathway
may be a multiprotein complex and another factor(s) may be
limiting. The identification of a S100 gene family member as a
component of a multiprotein Syn-1 and FGF-1 complex in ovine
brain (26) and the inhibition of the temperature stress-induced
release of FGF-1 and Syn-1 from cells treated with amlexanox
(26), an anti-inflammatory agent and S100A13-binding com-
pound (see Ref. 27 and GenBankTM accession number
AB001567), support this premise. The observation that p40
Syn-1 release is not dependent on the expression of FGF-1
suggests that Syn-1 or perhaps Syn gene family members may
also be involved in the regulation of other proteins that utilize
non-classical release pathways, such as FGF-2 and the inter-
leukin (IL)-1 prototypes IL-1a and IL-1b.
The p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfec-
tants exhibited the constitutive release of p40 Syn-1 at 37 °C.
Since treatment with 2-dOG only inhibits the potentiation of
p40 Syn-1 release after temperature stress, the 2-dOG data
suggest that only a small percentage of the p40 Syn-1 may be
able to access the non-classical FGF-1 release pathway (Fig.
7C). It is also possible that the soluble non-vesicular p40 Syn-1
may be able to enter the regulated non-classical release path-
way(s) through protein-protein interactions. This may occur by
potential interactions with endogenous p65 Syn-1, since the
C2B domain of Syn-1 has been demonstrated to self-associate
(28–30).
The constitutive release of p40 Syn-1 from p40-transfected
NIH 3T3 cells and the regulated release of p40 Syn-1 from
p65-transfected NIH 3T3 cells suggests that a protease may be
involved in the regulation of the FGF-1 and Syn-1 release
pathways. However, the generation of a soluble form of Syn-1 is
not the only requirement for release, since the p65-(del 120–
214) construct produces a p35 proteolytic fragment that is not
competent to enter the stress-induced release pathway. p65
Syn-1 has been characterized to contain a single hypersensitive
proteolytic site (between amino acids 111 and 112) in vitro, and
cleavage at this site results in the liberation of the extravesicu-
lar Syn-1 fragment from vesicles into the soluble fraction (12,
FIG. 7. The release of the extravesicular domain of Syn-1 from p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants. The
extravesicular domain of Syn-1 is constitutively secreted from p40 Syn-1 and FGF-1:b-gal co-transfected NIH 3T3 cells, and its secretion is
insensitive to brefeldin A. The p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell co-transfectants were treated, lysate and conditioned medium were
collected, and immunoblot analyses for Syn-1 (A) and FGF-1:b-gal (B) were performed as described under “Experimental Procedures.” A, Syn-1
immunoblot. Lanes 1 and 2 are the lysates from p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell transfectants at 37 °C untreated or treated with brefeldin
A, respectively. Lane 3 is 50 ng of recombinant rat Syn-1 extravesicular domain. Lanes 4 and 5 are conditioned medium collected from untreated
cells at 37 and 42 °C, respectively. Lanes 6 and 7 are conditioned medium collected from cells treated with brefeldin A at 37 and 42 °C, respectively.
Arrow indicates p40 Syn-1. B, FGF-1 immunoblot. Lanes 1 and 2 are the lysates from p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell transfectants at
37 °C untreated or treated with brefeldin A, respectively. Lanes 3 and 4 are conditioned medium collected from untreated cells at 37 and 42 °C,
respectively. Lanes 5 and 6 are conditioned medium collected from cells treated with brefeldin A at 37 and 42 °C, respectively. Arrow indicates
FGF-1:b-gal. C and D demonstrate the constitutive release of p40 Syn-1 at 37 °C is unaffected by treatment with 2-dOG; however, the potentiation
of p40 Syn-1 release in response to temperature stress is sensitive to treatment with 2-dOG. The p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell
co-transfectants were treated, lysate and conditioned medium were collected, and immunoblot analyses for Syn-1 (C) and FGF-1:b-gal (D) were
performed as described under “Experimental Procedures.” C, Syn-1 immunoblot. Lanes 1 and 2 are the lysates from p40 Syn-1 and FGF-1:b-gal
NIH 3T3 cell transfectants at 37 °C untreated or treated with 2-dOG, respectively. Lane 3 is 50 ng of recombinant rat Syn-1 extravesicular domain.
Lanes 4 and 5 are conditioned medium collected from untreated cells at 37 and 42 °C, respectively. Lanes 6 and 7 are conditioned medium collected
from cells treated with 2-dOG at 37 and 42 °C, respectively. Arrow indicates p40 Syn-1. D, FGF-1 immunoblot. Lanes 1 and 2 are the lysates from
p40 Syn-1 and FGF-1:b-gal NIH 3T3 cell transfectants at 37 °C untreated or treated with 2-dOG, respectively. Lanes 3 and 4 are conditioned
medium collected from untreated cells at 37 and 42 °C, respectively. Lanes 5 and 6 are conditioned medium collected from cells treated with 2-dOG
at 37 and 42 °C, respectively. Arrow indicates FGF-1:b-gal. LDH activity was measured to demonstrate that the cells did not undergo significant
lysis in the presence of the drugs and temperature stress: 37 °C, 4.0% and 42 °C, 7.2%; brefeldin A: 37 °C, 8.5% and 42 °C, 9.1%; and 2-dOG: 37 °C;
5.1% and 42 °C, 5.1%.
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31). Increasingly, intracellular proteases are proving to play
pivotal roles in the regulation of biological systems, such as the
cell cycle proteases in the regulation of cell growth (32), the
caspase family of proteases in the regulation of apoptosis (33),
and the chaperone-regulated proteases in the regulation of the
stress response (34). Indeed, proteases have been demon-
strated to play a role in the release pathways of IL-1b (35, 36)
and annexin-1 (37), two proteins that lack a signal sequence.
Whereas the components of the classical secretion pathway
are currently under characterization, non-classical secretion
pathways are not well defined. Recently, Cleves et al. (38)
expressed a mammalian protein, galectin-1, in yeast and iden-
tified three proteins that were involved in the non-classical
exocytosis of this protein, suggesting that non-classical secre-
tion pathways may also be evolutionarily conserved. However,
FGF-1 and FGF-2 utilize divergent exocytotic pathways, since
FGF-2 is not secreted in response to temperature stress (15)
and FGF-1 may utilize a nonvesicular exocytotic mechanism,
since the soluble p40 extravesicular portion of Syn-1 is secreted
with FGF-1. Although we do not know the mechanism that
FGF-1 and p40 Syn-1 use for release, both polypeptides bind
phosphatidylserine (7, 29, 39), which may enable them to in-
teract with the cytosolic face of membranes and, possibly, each
other. Deleting a region of the Syn-1 protein that contains the
phosphatidylserine-binding site, p65-(del 120–214), blocks the
release of both Syn-1 and FGF-1:b-gal and further suggests
that phosphatidylserine may play a role in this non-classical
release mechanism. Additionally, FGF-1 exhibits molten glob-
ule character at 42 °C which may allow FGF-1 to disrupt/
interrupt membrane structural integrity (40). Whether p40
Syn-1 exhibits a similar feature is not known; however, it had
recently been shown that the C2A domain of Syn-1 is able to
directly penetrate the lipid bilayer (41).
Acknowledgments—We thank the laboratories of R. Scheller (Stan-
ford University School of Medicine) for Syn-1 cDNA and T. Sudhof
(University of Texas Southwestern Medical Center) for Syn-1 cDNA
and antiserum. We also thank D. Weber and P. Foote for expert secre-
tarial support. We are grateful to Drs. Wilson Burgess, Susan Gar-
finkel, and Julia Tait Lathrop for critical reading of the manuscript.
REFERENCES
1. Burgess, W. H., and Maciag, T. (1989) Annu. Rev. Biochem. 58, 575–606
2. Forough, R., Xi, Z., MacPhee, M., Friedman, S., Engleka, K. A., Sayers, T.,
Wiltrout, R. H., and Maciag, T. (1993) J. Biol. Chem. 268, 2960–2968
3. Nabel, E. G., Yang, Z.-Y., Plautz, G., Forough, R., Zhan, X., Haudenschild,
C. C., Maciag, T., and Nabel, G. J. (1993) Nature 362, 844–846
4. Jackson, A., Friedman, S., Zhan, X., Engleka, K. A., Forough, R., and Maciag,
T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10691–10695
5. Jackson, A., Tarantini, F., Gamble, S., Friedman, S., and Maciag, T. (1995)
J. Biol. Chem. 270, 33–36
6. Engleka, K. A., and Maciag, T. (1992) J. Biol. Chem. 267, 11307–11315
7. Tarantini, F., Gamble, S., Jackson, A., and Maciag, T. (1995) J. Biol. Chem.
270, 29039–29042
8. Burgess, W. H., Mehlman, T., Friesel, R., Johnson, W., and Maciag, T. (1985)
J. Biol. Chem. 260, 11389–11392
9. Sudhoff, T. C., and Rizo, J. (1996) Neuron 17, 379–388
10. Kwon, O. J., Gainer, H., Wray, S., and Chin, H. (1996) FEBS Lett. 378,
135–139
11. Perin, M. S., Johnston, P. A., Ozcelik, T., Jahn, R., Francke, U., and Sudhof,
T. C. (1991) J. Biol. Chem. 266, 615–622
12. Perin, M. S., Brose, N., Jahn, R., and Sudhof, T. C. (1991) J. Biol. Chem. 266,
623–629
13. Kelly, R. B. (1995) Curr. Biol. 5, 257–259
14. Tarantini, F., LaVallee, T., Jackson, A., Gamble, S., Garfinkel, S., Mouta
Carreira, C., Burgess, W. H., and Maciag, T. (1998) J. Biol. Chem. 273,
22209–22216
15. Shi, J., Friedman, S., and Maciag, T. (1997) J. Biol. Chem. 272, 1142–1147
16. Kolodziej, P. A., and Young, R. A. (1991) Methods Enzymol. 194, 508–519
17. Martin, G. M., Sprague, C. A., and Epstein, C. J. (1970) Lab. Invest. 23, 86–92
18. Bergmeyer, H.-U. (1965) in Methods of Enzymatic Analysis (Bergmeyer, H.-U.,
ed) pp. 736–743, Academic Press, New York
19. Sano, H., Forough, R., Maier, J. A., Case, J. P., Jackson, A., Engleka, K.,
Maciag, T., and Wilder, R. L. (1990) J. Cell Biol. 110, 1417–1426
20. Bennett, M. K., Miller, K. G., and Scheller, R. H. (1993) J. Neurosci. 13,
1701–1707
21. Chapman, E. R., Blasi, J., An, S., Brose, N., Johnston, P. A., Sudhof, T. C., and
Jahn, R. (1996) Biochem. Biophys. Res. Commun. 225, 326–332
22. Li, C., Ullrich, B., Zhang, J. Z., Anderson, G. W., Brose, N., and Sudhof, T. C.
(1995) Nature 375, 594–599
23. Bennett, M. K., and Scheller, R. H. (1994) Annu. Rev. Biochem. 63, 63–100
24. Sutton, R. B. (1995) Cell 80, 929–938
25. Brose, N., Hofmann, K., Hata, Y., and Sudhof, T. C. (1995) J. Biol. Chem. 270,
25273–25280
26. Mouta Carreira, C., LaVallee, T., Tarantini, F., Jackson, A., Tait-Lathrop J.,
Hampton B., Burgess W. H., and Maciag, T. (1998) J. Biol. Chem. 273,
22224–22231
27. Oyama, Y., Shishibori, T., Yamashita, K., Naya, T., Nakagiri, S., Maeta, H.,
and Kobayashi, R. (1997) Biochem. Biophys. Res. Commun. 240, 341–347
28. Sugita, S., Hata, Y., and Sudhof, T. C. (1996) J. Biol. Chem. 271, 1262–1265
29. Chapman, E. R., An, S., Edwarson, J. M., and Jahn, R. (1996) J. Biol. Chem.
271, 5844–5849
30. Damer, C. K., and Creutz, C. E. (1996) J. Neurochem. 67, 1661–1668
31. Tugal, H. B., Leeuwen, F. V., Apps, D. K., Haywood, J., and Phillips, J. H.
(1991) Biochem. J. 279, 699–703
32. King, R. W., Deshaies, R. J., Peters, J.-M., and Kirschner, M. W. (1997) Science
274, 1652–1659
33. Miller, D. K. (1997) Semin. Immunol. 9, 35–49
34. Goldberg, A. L., Akopian, T. N., Kisselev, A. F., Lee, D. H., and Rohrwild, M.
(1997) Biol. Chem. Hoppe-Seyler 378, 131–140
35. Kostura, M. J., Tocci, M. J., Limjuco, G., Chin, J., Cameron, P., Hillman, A. G.,
Chartrain, N. A., and Schmidt, J. A. (1989) Proc. Natl. Acad. Sci. U. S. A.
86, 5227–5231
36. Wilson, K. P., Black, J. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia,
M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., and
Livingston, D. J. (1994) Nature 370, 270–275
37. Christmas, P., Callaway, J., Fallon, J., Jones, J., and Haigler, H. T. (1991)
J. Biol. Chem. 266, 2499–2507
38. Cleves, A. E., Cooper, D. N. W., Barondes, S. H., and Kelly, R. B. (1996) J. Cell
Biol. 133, 1017–1026
39. Perin, M. S., Fried, V. A., Mignery, G. A., Jahn, R., and Sudhof, T. C. (1990)
Nature 345, 260–263
40. Mach, H., and Middaugh, C. R. (1995) Biochemistry 34, 9913–9920
41. Chapman, E. R., and Davis, A. F. (1998) J. Biol. Chem. 273, 13995–14001
42. Davktov, B., Sontag, J. M., Haya, Y., Petrenko, A. G., Fyske, E. M., Jahn, R.,
and Sudhof, T. C. (1993) J. Biol. Chem. 268, 6816–6822
The FGF-1 Release Pathway II 22223
